JP2013515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515490A5
JP2013515490A5 JP2012546239A JP2012546239A JP2013515490A5 JP 2013515490 A5 JP2013515490 A5 JP 2013515490A5 JP 2012546239 A JP2012546239 A JP 2012546239A JP 2012546239 A JP2012546239 A JP 2012546239A JP 2013515490 A5 JP2013515490 A5 JP 2013515490A5
Authority
JP
Japan
Prior art keywords
lactic acid
composition
acid bacterium
antigen
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515490A (ja
Filing date
Publication date
Priority claimed from PCT/US2010/041792 external-priority patent/WO2011008735A1/en
Application filed filed Critical
Priority claimed from PCT/US2010/062034 external-priority patent/WO2011079282A1/en
Publication of JP2013515490A publication Critical patent/JP2013515490A/ja
Publication of JP2013515490A5 publication Critical patent/JP2013515490A5/ja
Pending legal-status Critical Current

Links

JP2012546239A 2009-12-23 2010-12-23 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護 Pending JP2013515490A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28966309P 2009-12-23 2009-12-23
US61/289,663 2009-12-23
PCT/US2010/041792 WO2011008735A1 (en) 2009-07-13 2010-07-13 Oral vaccines produced and administered using edible micro-organism
USPCT/US2010/041792 2010-07-13
PCT/US2010/062034 WO2011079282A1 (en) 2009-12-23 2010-12-23 Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules

Publications (2)

Publication Number Publication Date
JP2013515490A JP2013515490A (ja) 2013-05-09
JP2013515490A5 true JP2013515490A5 (https=) 2014-02-06

Family

ID=44196157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546239A Pending JP2013515490A (ja) 2009-12-23 2010-12-23 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護

Country Status (4)

Country Link
EP (1) EP2515661A4 (https=)
JP (1) JP2013515490A (https=)
CN (1) CN102665422B (https=)
WO (1) WO2011079282A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
CN102965388A (zh) * 2012-12-07 2013-03-13 山东信得科技股份有限公司 一种表达猪传染性胃肠炎病毒基因工程菌制备方法
AU2015244700B2 (en) 2014-04-10 2020-08-27 Riken Compositions and methods for induction of Th17 cells
CN104587458B (zh) * 2014-12-04 2017-01-04 吉林医药学院 预防贾第虫病的二价dna疫苗及其肠溶制剂
CN110511399B (zh) * 2019-07-26 2022-03-04 广西大学 一种控释型纳米纤维素抗菌微凝胶的制备方法
KR102254310B1 (ko) * 2019-10-02 2021-05-21 주식회사 고바이오랩 락토바실러스 애시도필러스 kbl409 균주 및 그 용도
CN116083240B (zh) * 2023-04-07 2023-08-29 深圳市第二人民医院(深圳市转化医学研究院) 工程化细菌及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017117A1 (en) * 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
EP0688205A1 (en) * 1993-03-11 1995-12-27 Secretech, Inc. Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
WO2000050078A1 (en) * 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
EP2422804A1 (en) * 2004-06-17 2012-02-29 Amano Enzyme USA., Ltd. Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
AR060565A1 (es) * 2006-04-21 2008-06-25 Dow Agrosciences Llc Vacuna para la gripe aviaria y metodos de uso
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
US20090149433A1 (en) * 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Similar Documents

Publication Publication Date Title
JP2013515490A5 (https=)
Grant et al. Human influenza viruses and CD8+ T cell responses
Altenburg et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
JP2014507482A5 (https=)
JP2013216685A5 (https=)
JP2016539946A5 (https=)
JP2012126742A5 (https=)
JP2011250797A5 (https=)
JP2012176990A5 (https=)
JP2008044945A5 (https=)
CN109563492A (zh) 突变的病毒、其制备方法和应用
Dong et al. Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
Banner et al. The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
MX351380B (es) Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino.
Lakdawala et al. Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets
JP2014511856A5 (https=)
Zhang et al. Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus
Avanthay et al. NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells
JP2010506926A5 (https=)
HRP20171697T1 (hr) Varijanta hiv gp-120
JP2016529316A5 (https=)
Cheng et al. Topical CpG oligodeoxynucleotide adjuvant enhances the adaptive immune response against influenza A infections
BR112013000996A2 (pt) proteína l1 hpv58 truncada ou variante da mesma, ácido nucleíco isolado, vetor, célula hospedeira, partícula do tipo viral hpv58, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv58 truncada, método para preparar a partícula do tipo viral hpv58, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada por infecção hpv, e uso da proteína l1 hpv58 truncada ou variante da mesma